TN

Thomas Needham

Director at Broadview Ventures Inc

Greater Boston

Overview 

Thomas Needham is currently the Director at Broadview Ventures Inc in Greater Boston, with a background in business and corporate development in the lifesciences industry. With experience in roles such as Chief Business Officer at Merrimack and Senior Vice President at C4 Therapeutics, he has successfully led M&A activities, commercialization strategies, and venture capital investments in biopharmaceutical companies. Notable highlights of Thomas Needham's career include his expertise in acquisition integration and his track record of investing in promising companies like IsomAb at the seed stage, showcasing his strong leadership in advancing innovative healthcare solutions.

Work Experience 

LV

Longview Ventures

  • Managing Director

    2025 - Current

    Managing Director of Longview Ventures, an independent investment vehicle focused on clinical-stage opportunities, as a complement to Broadview's dedication to Seed and Series A financings.

  • Director, Head of BioPharma

    2019 - 2025

BV

Broadview Ventures Inc

  • Director, Head of BioPharma

    2018

    Head of the BioPharmaceuticals practice managing the firm's biotechnology investment strategy and activity, from identification and screening of new opportunities, through due diligence, deal structure and syndication, portfolio company board management roles and overarching portfolio strategy.

Broadview Ventures invests in businesses that focus on the development of technology solutions in cardiovascular and neurovascular diseases.

broadviewventures.org
AP

Alveron Pharma

  • Board Observer

    2024

IL

Isomab Ltd

  • Board of Directors, Member

    2024

BB

Basking Biosciences Inc

  • Board of Directors, Member

    2023

  • Chairman, Board of Directors

    2020 - 2023

CB

Comanche Biopharma

  • Board Observer

    2021

Our purpose is to make every pregnancy around the world safer.

Raised $111,100,007.00 from Atlas Venture, F-Prime Capital, Lilly Asia Ventures, Google Ventures, New Enterprise Associates and Longview Ventures.

comanchebiopharma.com
HT

HAYA Therapeutics

  • Board Observer

    2020

AT

Antag Therapeutics

  • Board Observer

    2023 - 2024

  • Board of Directors, Member

    2020 - 2023

R

Renovacor

  • Board of Directors, Member

    2021 - 2022

  • Chairman, Board of Directors

    2019 - 2021

    Renovacor (NYSE: RCOR) acquired by Rocket Pharmaceuticals (Nasdaq: ROCK)

Kantum Bio

  • Board of Directors, Member

    2021 - 2022

  • Board Observer

    2018 - 2021

Education 

Investments 

IsomAb

Seed

Total funding: $9M

Articles About Thomas

Relevant Websites